Tysabri, an aggressive treatment for multiple sclerosis, has had a history of infamy. It is associated with causing a rare neurological virus, progressive multifocal leukoencephalopathy, in a handful of patients. After two years back on the market, it has nevertheless helped many patients who do not respond to the traditional disease-modifying meds (Avonex, Betaseron, Copaxone, or Rebif.) For the full story, read Lisa Emrich’s entry about the recent situation (her blog, “Brass and Ivory”, provides insightful information about pharmaceutical corporations and health insurance issues important to those with multiple sclerosis and other chronic health conditions.)
